Efficacy
TUMOR GROWTH
Fifteen patients completed the full 12-month study period and were available to evaluate the primary end point of difference in tumor growth between treatment and observations periods; there was not a significant difference (8.4%; 95% CI, 1.5%-15.3% vs 4.0% 95% CI, −0.1% to 8.0%; 